Product showcased at Health Ingredients Europe

RNS Number : 2343Y

OptiBiotix Health PLC

28 November 2014

 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

OptiBiotix showcases weight management product at Health Ingredients Europe

OptiBiotix Health plc(AIM: OPTI), the Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that its weight management yoghurt will be showcased at the Health Ingredients Europe conference in Amsterdam from December 2^nd - 4^th 2014. The product will be available on the Nizo Food Research stand and will be supported by product samples. The stand number is J2.

Health Ingredients Europe (HiE) is the largest European exhibition for health ingredients, with more than 500 global suppliers registered to attend.  HiE promotes itself as the leading European venue to engage with business partners and solution providers in the $1 trillion health, natural and nutritional food and beverage industry.

The weight management yoghurt brings together the joint expertise of OptiBiotix Health and Nizo Food Research. OptiBiotix is responsible for the weight management formulation, created by world experts in satiation (the feeling of fullness), metabolism and how microbes harvest energy in the gut whilst Nizo's specialist expertise lies in the manufacture of dairy products and using taste and texture to improve satiation.

Stephen O'Hara, CEO of OptioBiotix Health plc commented: "We are delighted to be presenting our unique weight management product at this year's HiE exhibition and exploring partnership opportunities with the many global suppliers attending this exhibition."

OptiBiotix Health plc	www.optibiotix.com
Stephen O'Hara, Chief Executive	Contact via Walbrook below
Peterhouse Corporate Finance Ltd	Tel: [phone]
Lucy Williams / Duncan Vasey
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]
Mike Wort	Mob: [phone]

About OptiBiotix- www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About NIZO - www.nizo.com

NIZO is one of the most advanced, independent contract research companies in the world and works with both small and multinational food and ingredient companies to develop and produce innovative products for the food and drink industry. NIZO has one of the largest food-grade pilot plants in Europe, and more than 65 years' experience and expertise in product manufacture

 

END

 

 

NRAFEFFMWFLSELF